Roche and AmoyDx reached a strategic cooperation

August 11, the Second Roche Pan-Tumor Precision Diagnosis and Innovation Ecology Forum was officially opened at Roche Pharma China Shanghai Campus, where participants discussed solutions for pan-tumor precision diagnosis and treatment. At this forum, AmoyDx and Roche Pharmaceuticals reached a strategic cooperation to jointly promote the development of an open, cooperative and innovative local medical and health ecosystem and provide patients with more accurate digital medical solutions. At the same time, Dr. Zhu Guanshan, deputy general manager of AmoyDx, was invited to participate in the Roche Pan-Tumor Precision Diagnosis and Innovation Ecological Forum, and expressed his views on the understanding of pan-tumor precision diagnosis and how to establish an effective patient diagnosis path.

July 29, Roche Pharma's pan-tumor anti-cancer drug entrectinib, which is not limited to cancer types and targets the rare target NTRK in solid tumors, was approved in China, bringing innovative personalized medical solutions to more Chinese tumor patients. The solution will help the precise diagnosis and treatment of tumors to reach a new level. This time, AmoyDx and Roche Pharmaceuticals have reached a strategic cooperation, and will jointly work on the establishment of a genetically precise diagnosis and treatment path for pan-tumor patients, helping patients obtain individualized and precise diagnosis and treatment, and maximize patient benefits.

About Roche Pharmaceuticals

Roche is a leading global biotechnology company headquartered in Switzerland with a history of more than 125 years. Combining our unique strengths in pharmaceuticals and diagnostics, we are committed to advancing science and improving human life through personalized medicine. Roche Pharma China was established in 1994. As the first multinational company to settle in Shanghai Zhangjiang Hi-Tech Park, Roche Pharma is a market leader in key fields such as anti-tumor, anti-infection, transplantation, rheumatology and neuroscience. At present, Roche has 25 products in China, covering 8 major therapeutic areas. Among large multinational pharmaceutical companies, Roche is the first in China to build and continuously upgrade and improve a complete pharmaceutical value industry chain including research, development, production, marketing and other links. At the same time, Roche has also joined hands with the government, medical institutions, and NGOs from all walks of life to explore innovative cooperation models and benefit more Chinese patients through a series of influential and sustainable measures.

About AmoyDx

Xiamen AmoyDx Technology Co., Ltd. (stock code: 300685) focuses on the field of molecular diagnosis of tumor precision medicine, technological innovation of science and technology to benefit the people, and is committed to providing patients with compliant and high-quality diagnostic products and services. Real benefits from precision medicine. The company has won the qualifications of the National Enterprise Technology Center, the Ministry of Industry and Information Technology, the Specialized New Little Giant Enterprise, and the Postdoctoral Research Station. It has more than 60 independent patented technologies, and the core technology has been authorized by China, the United States, the European Union, and Japan, and won the Chinese National Science and Technology Progress Award II. First prize, Silver Award of China Patent Award; products cover all major cancer types with precision medical conditions, and many products have no competing products so far. In addition to large-scale applications in Chinese Grade A tertiary hospitals, some products have been approved for listing in Japan and South Korea. Entering the local medical insurance has created a precedent for the overseas approval of Chinese tumor companion diagnostics. In addition, the company has two medical testing laboratories in Xiamen and Shanghai. It has a medical institution practice license, has passed the American College of Pathology (CAP) certification and ISO15189 accreditation, and specializes in third-party clinical inspection services. At present, AmoyDx products have entered dozens of countries and regions around the world, benefiting hundreds of thousands of cancer patients every year. The company's brand and reputation have been recognized internationally. It is a strategic partner of many top pharmaceutical companies in the development of oncology drugs, and is an internationally renowned national brand.